BioventusvsEli Lilly and Company

BVS and LLY stock compared: price, dividend, valuation and results, from SEC filings.

BVS

Bioventus Inc.

$10.66

Value $710M

-1.84%
BVS's page

LLY

Eli Lilly and Company

$1,443.50

Value $1.36T

+1.14%
LLY's page

Bioventus (BVS) has a market value of $710M and Eli Lilly and Company (LLY) $1.36T. Over the last year, with dividends, BVS moved +39.3% and LLY +42.9%. Dividend yield: BVS none, LLY 0.44%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BVS$710M

    LLY$1.36T

    LLY is 1,917 times BVS

  • Revenue, 12 months

    BVS$586M

    LLY$86.5B

    LLY is 148 times BVS

  • Net income, 12 months

    BVS$57M

    LLY$27.6B

    LLY is 481 times BVS

  • Operating margin

    BVS9.7%

    LLY–

  • ROIC

    BVS9.4%

    LLY35.5%

    26.1 points apart

  • P/E

    BVS–

    LLY49.4

  • Dividend yield

    BVS0.0%

    LLY0.4%

    0.4 points apart

  • 5-year return

    BVS-32.7%

    LLY+480.4%

    513.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BVS-32.7%

LLY+480.4%

020040060020222023202420252026
Returns by period
PeriodBVSWith dividendsLLYWith dividends
1 year since November 12, 2025+39.3%Price +39.3%+42.9%Price +41.8%
3 years since November 13, 2023+188.1%+42.3% a yearPrice +188.1%+140.8%+34.0% a yearPrice +135.6%
5 years since November 12, 2021-32.7%-7.6% a yearPrice -32.7%+480.4%+42.2% a yearPrice +455.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BVSBioventusLLYEli Lilly and Company

Valuation

BVSLLY
Valuation
Price$10.66$1,443.50
Market value$710M$1.36T
Enterprise value (EV)$918M$1.41T
P/E–49.4
P/E, 5-year median–49.9
P/B3.033.8
EV/EBIT16.240.5
Free cash flow yield12.0%1.4%

Results and growth

BVSLLY
Results and growth
Revenue, 12 months$586M$86.5B
Net income, 12 months$57M$27.6B
Free cash flow, 12 months$85M$19.7B
Earnings per share, 12 months$0.80$30.81
Revenue growth, year on year-0.9%44.7%
Revenue growth a year, past+12.1%over 5 years+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

BVSLLY
Margins and returns on capital
Gross margin68.7%83.6%
Operating margin9.7%–
Net margin9.8%31.9%
ROIC9.4%35.5%
ROE28.4%88.6%

Balance sheet

BVSLLY
Balance sheet
Cash$31M$4.9B
Total debt$244M$49.5B
Net debt / EBITDA2.01.2
Interest cover–38.9×

Dividends and buybacks

BVSLLY
Dividends and buybacks
Dividend yield–0.4%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BVS or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Bioventus or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.36T) is about 1,917.4 times Bioventus ($710M), at today's prices.

How did BVS and LLY stock do over the last 5 years?

Since November 12, 2021, BVS's price moved -32.7% and LLY's +455.9%. With dividends: BVS -32.7% (-7.6% a year), LLY +480.4% (+42.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, BVS or LLY?

The dividend yield at today's price is none for Bioventus and 0.44% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Bioventus or Eli Lilly and Company?

Over the last twelve months, the net margin was 9.8% for Bioventus and 31.9% for Eli Lilly and Company, and the operating margin 9.7% and –. Revenue was $586M and $86.5B.

Which is the better investment, Bioventus or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.